Flagship Ventures Fund V General Partner LLC

SEC CIK: 0001724575

SEC filings (opens in a new tab)

No open-market purchases or sales filed in the past year.

Current role at each company

FHTX Foghorn Therapeutics Inc.Director, 10% Owneras of Jan 15, 2026
SANA Sana Biotechnology, Inc.10% Owneras of Sep 15, 2023
SGTX Sigilon Therapeutics, Inc.10% Owneras of Aug 15, 2023
CDAK Codiak BioSciences, Inc.10% Owneras of Sep 16, 2022
OMGA Omega Therapeutics, Inc.10% Owneras of Aug 5, 2021

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought: –; 0 filings
Sold: –; 0 filings
Net: –; Bought minus sold
Companies: 0; With open-market trades

Trades

Every Form 4 that lists Flagship Ventures Fund V General Partner LLC as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

Transaction type

Role

Minimum value (USD)

Filed from

Filed to

Filing delay at least (days)

Filing delay at most (days)

SANA Sana Biotechnology, Inc.

10% Owner2 trades

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Jun 8, 2023 (view filing)7:00 PM ET	Jun 6-7	2 days	Afeyan Noubar and 3 others10% Owner	SSale	−403.8K	$6.27	−$2.53M	−22.6%1.38M after	4 lots
May 26, 2023 (view filing)8:00 PM ET	May 24-26	2 days	Afeyan Noubar and 3 others10% Owner	SSale	−545.2K	$6.47	−$3.53M	−27.7%1.43M after	6 lots

CDAK Codiak BioSciences, Inc.